Monday, Jan 21, 1991

Xenova and Genentech Expand Their Research and Development Collaboration

Slough, Berkshire, United Kingdom -- January 21, 1991 --

Xenova, Ltd. and Genentech, Inc. have today announced important developments in their collaborative discovery programme, first described in May 1989.

This collaboration, focused on the discovery of small molecule therapeutics, has been expanded following the emergence of promising leads from the initial programme. A further six molecular targets have been added to the four initially selected for the programme, and both partners will substantially increase programme staffing and resources. Genentech will have exclusive rights to develop and market products in the United States, with Genentech and Xenova sharing rights in the rest of the world.

The initial project incorporated targets in the areas of cardiovascular diseases and growth control, combining Genentech's capabilities in recombinant DNA and protein chemistry with Xenova's technology in receptor targeted screening. A number of small molecule leads have been identified and are undergoing further biomolecular and physiological evaluation.

Commenting on the announcement, Dr. Arthur Levinson, vice president of research, Genentech, Inc., said, "The expansion of this programme confirms Genentech's intention to be at the forefront in developing the next generation of biotechnology products. In Xenova, we have found an innovative and productive partner whose product discovery technologies complement our own."

Dr Louis Nisbet, Xenova's CEO said, "The relationship with Genentech is strategically important for Xenova, and is proving immensely rewarding to the scientists from both companies. The expanded project represents a major commitment to provide therapeutic advances for some of today's most challenging diseases."

Xenova is a pharmaceutical research and development company specializing in the discovery of novel, pharmacologically active compounds from microorganisms. Xenova utilizes recent advances in molecular biology and diagnostic technology to develop effective screening procedures for innovative natural products having applications in the pharmaceutical and agrochemical markets.

Genentech, based in South San Francisco, Calif., is a leading biotechnology company focusing on the development, manufacture and marketing of pharmaceuticals produced by recombinant DNA technology.

# # #